title: Xylo-oligosaccharide (XOS) in combination with inulin modulates both the intestinal environment and immune status in healthy subjects, while XOS alone only shows prebiotic properties.
abstract: The purpose of the present study was to establish the prebiotic effect of a new xylo-oligosaccharide (XOS) and of an inulin-and-XOS mixture (INU-XOS) and to determine their effect on endotoxaemia (lipopolysaccharides (LPS)) and immune parameters. In this randomised, parallel, placebo-controlled, double-blind study, sixty healthy volunteers were randomly assigned to three groups, receiving either 5 g XOS, INU-XOS (3 g inulin +1 g XOS) or an equivalent weight of wheat maltodextrin (placebo) during 4 weeks. Faecal samples were collected to assess the effects of these products on microbiota, as well as SCFA composition, enzymatic activities and secretory IgA production. Circulating LPS was measured in plasma samples, and whole blood was incubated with LPS to measure cytokine expression. Consumption of XOS alone increased the faecal concentrations of Bifidobacterium and butyrate and activities of α-glucosidase and β-glucuronidase, while decreasing the concentrations of acetate and p-cresol. Consumption of XOS in combination with inulin did not decrease the concentrations of acetate and p-cresol, but increased in addition the faecal concentrations of total SCFA and propionate. Furthermore, consumption of XOS in combination with inulin decreased LPS concentrations in blood and attenuated LPS-induced increases in gene expression in IL-1β and LPS-induced decreases in gene expression in IL-13 in blood. In conclusion, consumption of XOS alone or in combination with inulin results in beneficial albeit different changes in the intestinal microbiome on a high-fat diet. In addition, consumption of XOS in combination with inulin attenuates the proinflammatory effects of a high-fat diet in the blood of healthy subjects.
authors.affiliation: Nutrition Department, Institut Pasteur de Lille, 1 rue du Professeur Calmette, BP 245, 59019 Lille Cedex, France. jean-michel.lecerf@pasteur-lille.fr
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Lecerf
authors.forename: Flore
authors.initials: F
authors.lastname: Dépeint
authors.forename: Elise
authors.initials: E
authors.lastname: Clerc
authors.forename: Yann
authors.initials: Y
authors.lastname: Dugenet
authors.forename: Claude N
authors.initials: CN
authors.lastname: Niamba
authors.forename: Larbi
authors.initials: L
authors.lastname: Rhazi
authors.forename: Amélie
authors.initials: A
authors.lastname: Cayzeele
authors.forename: Ghenwa
authors.initials: G
authors.lastname: Abdelnour
authors.forename: Arnaud
authors.initials: A
authors.lastname: Jaruga
authors.forename: Hassan
authors.initials: H
authors.lastname: Younes
authors.forename: Heidi
authors.initials: H
authors.lastname: Jacobs
authors.forename: Guy
authors.initials: G
authors.lastname: Lambrey
authors.forename: Afif M
authors.initials: AM
authors.lastname: Abdelnour
authors.forename: Philippe R
authors.initials: PR
authors.lastname: Pouillart
mesh_terms: D000293:Adolescent; D000818:Animals; D001644:Bifidobacterium / Q000302:isolation & purification; D019587:Dietary Supplements; D004311:Double-Blind Method; D004338:Drug Combinations; D005243:Feces / Q000737:chemistry / Q000382:microbiology; D005260:Female; D006801:Humans; D007444:Inulin / Q000008:administration & dosage / Q000494:pharmacology*; D008297:Male; D009844:Oligosaccharides / Q000008:administration & dosage / Q000494:pharmacology*; D056692:Prebiotics; D055815:Young Adult
chemical_list: D004338:Drug Combinations; D009844:Oligosaccharides; D056692:Prebiotics; D007444:Inulin